Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ITIL-168

Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells, directed at tumor cells · developed by Instil Bio

Phase 2 Most advanced trial (none active)

TIL Developer

1 Registered trials

What is ITIL-168?

ITIL-168 is an autologous tumor infiltrating lymphocyte (TIL) cell therapy derived from each patient's own tumor. The engineered TILs are expanded ex vivo and reinfused to recognize and kill the patient's tumor cells. It is being studied in advanced cutaneous melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (Tumor-infiltrating lymphocytes)
Targets: tumor cells (antigen)
Mechanism: Kills target cells, directed at tumor cells
Therapy area: Oncology
Developer: Instil Bio (TIL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05050006	Phase 2	Advanced Cutaneous Melanoma	Terminated	TIL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Cutaneous Melanoma

More from Instil Bio

ITIL-306 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TIL page.

Follow TIL, the company behind ITIL-168

See TIL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TIL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z